ACHILLION PHARMACEUTICALS INC
ACHN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ACHN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Sep 30, 2019.
Tracking 2 pipeline candidates for ACHILLION PHARMACEUTICALS INC.
Run ACHILLION PHARMACEUTICALS INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ACHILLION PHARMACEUTICALS INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
27.2 months
D/E 0.09
Lead: Phase 2
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Governance
Frequently asked questions
What is ACHILLION PHARMACEUTICALS INC's lead drug candidate?
ACHILLION PHARMACEUTICALS INC's most advanced tracked candidate is ach-4471 (Phase 2) for C3 glomerulopathy (C3G), immune complex membranoproliferative glomerulonephritis (IC-MPGN), and paroxysmal nocturnal hemoglobinuria (PNH).
Who is the CEO of ACHILLION PHARMACEUTICALS INC?
Intarcia Therapeutics is the chief executive officer of ACHILLION PHARMACEUTICALS INC (ACHN).
What therapeutic areas does ACHILLION PHARMACEUTICALS INC focus on?
ACHILLION PHARMACEUTICALS INC develops therapies across Rare Disease, Hematology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.